BLUJEPA- the antibiotic approved for use in March 2025

The FDA approved BLUJEPA (gepotidacin) for uncomplicated urinary tract infections this year.It is used to treat women and girls over the age of 12 for uncomplicated urinary tract infections.

The bacteria that most commonly cause UTIs are slowly becoming resistant to most of the drugs that are currently in use for UTI. So the emergence of a new drug for the same sounds promising.

The side effects include heart rhythm problems, muscle spasms, weakness.

In your experience, is there a pressing need to develop novel antibiotics for UTIs?

MBH/PS

1 Like

Absolutely! rising antibiotic resistance makes developing new, targeted therapies for UTIs more urgent than ever.

1 Like